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Germany; cImmunisation Unit, Robert Koch Institute, Berlin, Germany; dDepartment of Quantitative Methods in Public Health, EHESP Rennes,
Sorbonne Paris Cité, Rennes, France; eUPRES-EA-7449 Reperes, University of Rennes 1, Rennes, France; fICON Health Economics and Epidemiology,
Oxford, UK; gDepartment of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands;
hDepartment of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; iInstitute of Science in
Healthy Aging & healthcaRE (SHARE), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
ABSTRACT
Background: Quadrivalent influenza vaccines (QIVs) contain antigens derived from an additional
influenza type B virus as compared with currently used trivalent influenza vaccines (TIVs). This should
overcome a potential reduced vaccine protection due to mismatches between TIV and circulating B
viruses. In this study, we systematically reviewed the available literature on health economic evaluations
of switching from TIV to QIV.
Areas covered: The databases of Medline and Embase were searched systematically to identify health
economic evaluations of QIV versus TIV published before September 2016.A total of sixteen studies
were included, thirteen cost-effectiveness analyses and three cost-comparisons.
Expert commentary: Published evidence on the cost-effectiveness of QIV suggests that switching from
TIV to QIV would be a valuable intervention from both the public health and economic viewpoint.
However, more research seems mandatory. Our main recommendations for future research include: 1)
more extensive use of dynamic models in order to estimate the full impact of QIV on influenza
transmission including indirect effects, 2) improved availability of data on disease outcomes and
costs related to influenza type B viruses, and 3) more research on immunogenicity of natural influenza
infection and vaccination, with emphasis on cross-reactivity between different influenza B viruses and
duration of protection.
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Seasonal influenza is a contagious acute respiratory infection,
causing every year up to five million cases of severe illness and
half a million deaths globally [1]. In addition, the economic
burden of seasonal influenza is considerable. In the United
States (US) for instance annual costs of US $10.4 billion in
health-care utilization and US $16.3 billion in work absentee-
ism are caused by influenza [2]. Seasonal influenza can be
caused by influenza type A viruses and influenza type B
viruses. Although the majority of influenza cases are caused
by influenza type A viruses (A/H1N1 and A/H3N2), the burden
of influenza type B viruses has been shown to be substantial.
Since 2001, two antigenically distinct lineages of influenza B
viruses, B/Victoria (B/Vic) and B/Yamagata (B/Yam), circulate
worldwide on an irregular basis, being responsible for 20–25%
of all influenza cases [3–5].
To reduce seasonal influenza epidemics, most industrialized
countries implemented influenza immunization strategies.
Trivalent influenza vaccines (TIVs) contain antigens derived
from two influenza A virus subtypes (A/H1N1 and A/H3N2)
and one influenza type B virus (either B/Vic or B/Yam). Each
year it is decided which influenza B lineage should be
included, based on predictions of the World Health
Organization (WHO) about the anticipated dominant influenza
type B virus [1]. However, in the seasons 2001–2002 until
2010–2011, mismatches between the vaccine and the circulat-
ing B viruses have occurred in half of the seasons, while in
some seasons co-circulation of both lineages was noticed [3].
Therefore, quadrivalent influenza vaccines (QIVs) have been
developed and were first licensed in 2012 [6], containing
strains of both influenza B lineages (B/Vic as well as B/Yam).
Currently, some countries already include QIV next to TIV in
their vaccination recommendations, like the US, Canada, and
Australia [7–9]. The United Kingdom (UK) extended the influ-
enza vaccination program to children using the quadrivalent
live-attenuated influenza vaccine (Q-LAIV) [10]. However, in
many other countries, including most European countries,
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TIV is still used because either QIV is not yet available, QIV
procurement agreements with health-care providers might
still be ongoing [11], or potential added benefits of QIV are
not or not yet recognized by national immunization technical
advisory groups (NITAGs).
A decision about switching from TIV to QIV is based on
various criteria, of which a beneficial cost-effectiveness profile
is often one of the principal aspects being considered by
NITAGs in Europe [12]. Such cost-effectiveness assessments
usually rely on mathematical models aiming to predict the
impact of vaccination strategies on mortality, health-related
quality of life, and costs to the health-care sector and society.
In 2014, key issues and challenges relating to the determina-
tion of the impact and cost-effectiveness of quadrivalent influ-
enza vaccination have already been described by Quinn et al.
[13]. The authors recommended the use of subtype- and age-
specific estimates of influenza disease burden and costs,
because these estimates can differ between influenza A and
B viruses across age-groups. Moreover, the existence of cross-
protection from TIV against the unmatched B-lineage was
discussed, potentially diminishing the relative impact of quad-
rivalent influenza vaccination. Finally, it was stated that the
use of dynamic models would be important, as this modeling
approach includes by definition indirect effects to the unvac-
cinated part of the population, which is of crucial relevance to
the impact of vaccination.
To the best of our knowledge, two studies summarized the
literature on the comparison of QIV versus TIV [13,14].
However, the corresponding searches seem not to be sys-
tematic. Moreover, a variety of economic evaluations of QIV
versus TIV have subsequently been published. Therefore, we
aimed to systematically review the literature on the economic
value of QIV in order to analyze a potential switching from TIV
to QIV, including the most recent publications. In addition, we
aimed to identify gaps in the current knowledge and needs for
future research.
2. Methods
2.1. Search strategy and study selection process
A literature search was performed in the Medline and Embase
databases to identify relevant articles on the comparison of
the health economic impact of QIV versus TIV that were
published before 30 September 2016. Key words of the search
included terms like influenza, quadrivalent, cost-effectiveness,
cost-utility, cost-benefit, economic evaluation, and model. The
full search strings can be found in the supplemental material
and contained free text searching terms as well as controlled
terms. We screened on titles and abstracts and eventually
reviewed the full content of each eligible article. Also refer-
ence lists of eligible studies and review papers discussing the
value of QIV were searched (snowballing).
Our selection criteria were that studies should contain
original full economic evaluations of QIV versus TIV using a
health-economic decision model. We considered studies of all
age-groups and vaccine types. In order to be selected, studies
had to include an economic comparison between QIV and TIV,
or separately report outcomes for QIV and TIV that allowed
calculation of this comparison by us. We limited our review to
the English language. Abstracts of congress meetings, editor-
ials, letters, and reviews were excluded.
2.2. Synthesis of results
The included papers were screened independently by two
reviewers (BMvM and PTdB). First, the reporting quality of the
studies was assessed using the Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) checklist [15]. Then,
the following information was systematically extracted if possi-
ble/reported: (1) country of study, funding source, general char-
acteristics of the analysis (type of analysis, model type,
perspective, time horizon, currency and price year, discount
rate, type of sensitivity analyses, and model validation perfor-
mances); (2) target group and main features of the vaccination
program (coverage and vaccine price) and vaccine characteris-
tics (vaccine efficacy, level of cross-protection of TIV against the
opposite type B virus, and duration of protection); (3) influenza-
related characteristics (attack rate, details on outcomes, dura-
tion of immunity, influenza-related health effects, details on
health-care costs, and work days lost); and (4) main study out-
comes (reduction of influenza cases, reduction of influenza-
related deaths, incremental cost-effectiveness/cost-utility ratios,
and key drivers of cost-effectiveness outcomes). It is important
to note that the terms cost-effectiveness and cost-utility are
interchangeably used in this review. Reported model validation
techniques were assessed using the AdVISHE, a tool containing
a structured list of relevant items for validation [16]. This check-
list includes five validation categories, that is, validation of the
conceptual model, input data, computerized model, model out-
comes, and ‘other’ validation techniques. Any model validation
effort that was described in the economic evaluation was then
extracted. To enhance comparability between studies, cost-out-
comes were transferred to the 2015 price year using national
consumer price indexes [17] and then converted to US $ using
purchasing power parities [18]. If the costing year was not
provided in the study, we assumed a costing year of ‘publica-
tion year minus 3 years.’ The reporting of our review was
performed according to the PRISMA statement [19]. However,




The initial search in the databases of Medline and Embase
resulted in a total of 49 studies, of which 35 remained after
removing duplicates. Of these 35 studies, 2 studies were
excluded after screening titles and abstracts, and from 18
studies no full-text was available as these referred to confer-
ence abstracts only. As one additional study that met our
inclusion criteria was identified outside the initial search, we
ended up with 16 eligible studies [20–35]. The flowchart of the
study identification process is displayed in Figure 1. One study
comprised a main paper and a corrigendum [27,36]. Of these
16 studies, 2 did not primarily focus on the cost-effectiveness
of QIV as compared with TIV, but on high-dose TIV [21] or




























adjuvanted TIV [29] as compared with TIV and QIV. However,
as both studies reported detailed results of TIV and QIV, we
included these studies in our review. Outcomes on QIV versus
high-dose TIV or versus adjuvanted TIV were not included in
this review, but are briefly described in the discussion section.
Overall, the reporting quality of the studies was found to
be acceptable (see Table S1 for detailed scores per checklist
item). A total of 13 out of 16 studies were ranked as good,
adhering to more than 17 out of 24 items on the CHEERs
checklist [20–26,28–31,33,35], while 3 studies were assessed
as moderate, adhering to less than 17 out of 24 points
[27,32,34]. Arguments for the choice of time-horizon and
model-type were most often not reported. Also details on
instruments used and populations involved to estimate the
impact of influenza on quality-of-life were not presented in
the majority of studies.
3.2. Study characteristics
A summary of the general study characteristics is given in
Table 1. All studies were conducted in industrialized countries,
including the US [21–23,27,29], UK [28,31,33], Canada [20,31],
Spain [25], Finland [30], Australia [26], Germany [24], and Hong
Kong [34,35]. One study analyzed the economic impact of QIV
in 5 countries of the European Union (EU) and extrapolated
this to all 27 EU countries [32]. Out of the 16 studies, 13 were
funded by manufacturers [20–26,28–33], 1 was funded by
public sources [27], and 2 studies were conducted without
reporting any specific funding [34,35]. A total of 13 studies
performed a cost-utility analysis [20–25,28–31,33–35], expres-
sing results as costs per QALY gained. The remaining three
studies conducted cost-comparisons [26,27,32].
Five studies used a dynamic modeling approach
[23,24,29–31]. For three of these five studies, a more detailed
description of the dynamic model was previously published
[37–39]. Dynamic models simulate the transmission dynamics
of influenza within the population and take into account age-
stratified mixing patterns between different population
groups, summarized in a ’contact matrix.’ These models
were compartmental SIR models (or extensions of such mod-
els), dividing the population between susceptible (S),
infected (I), and recovered/immune (R), while adding a vacci-
nated compartment to account for those individuals pro-
tected by vaccination. By definition, dynamic models are
able to account for both direct effects of vaccination and
indirect effects on the vaccinated and the non-vaccinated
Articles included from 
Medline  
n = 18 
Articles included from 
Embase 
n = 31 
Total articles included  
n = 49 
Duplicates 
n = 14 
Unique articles included  
n = 35 
Excluded on title or abstract 
n = 2 
Articles included on title 
and abstracts  
n = 33 
Excluded on full text not 
available 
 n = 18 
Articles included from 
Medline and EMBASE 
n = 15 
Identified outside search and 
included 
n = 1
Total articles included and 
reviewed 
n = 16
Figure 1. Flowchart of the study selection process.



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































population, for example, herd protection or potential age
shifts regarding incidence peaks [40,41]. The other 11 studies
used static models [20–22,25–28,32–35]. Three of these 11
studies used the same Markov model [25,28,33] developed
by van Bellinghen et al. [33], while 6 studies
[20,21,26,27,32,34] followed and extended the approach
that was explained in the online available spreadsheet-
based model by Reed et al. [42]. All of the static modeling
studies neglected indirect effects.
The societal perspective was the most considered per-
spective [20–30,32,34,35], including direct medical costs and
indirect costs due to productivity losses. Other perspectives
that were used concerned the payers perspective, comprising
medical costs only [20,23,24,26–28,30–33,35]. Notably, some
studies evaluated the decision problem from more than one
perspective. Next to the perspective, the studies’ time hor-
izons present a core issue, with the longer time horizon
generally being preferred but requiring long-term data and/
or additional assumptions. The time-horizon varied across
studies from one year to a lifetime. Four studies performed
a retrospective analysis in which the additional benefit of QIV
was estimated over 10 influenza seasons [26,27,32,34]. In
some dynamic models, the total analysis time is longer than
the time horizon (i.e. evaluation period) because of a ‘burn-
in’/’run-in’ period [23,24,30,31]. This burn-in period is used to
allow the model’s dynamic behavior to settle down before
the analysis between TIV and QIV is undertaken. For instance,
in the study of Dolk et al. [24], each simulation ran for
40 years. The first 20 years were used for initializing age-
dependent infection and immunity patterns in the popula-
tion and the final 20 years for studying the intervention of
QIV versus TIV.
All studies except one applied an equal discount rate for
costs and health effects, ranging from 3% for the US
[21,22,27,34,35], Finland [30], and Spain [25], to 5% for
Canada [20,31]. Only the study for Germany used differential
discount rates, that is, 3% for costs and 1.5% for health effects
[24]. Three studies reported a discount rate for health effects
only [29,34,35], as they limited discounting to life-years gained
of influenza-related deaths. Two studies analyzing the impact
of QIV retrospectively did not apply discounting [26,32].
To accommodate for uncertainty of relevant parameters
in the model, most studies performed sensitivity analyses. A
total of 13 studies performed a probabilistic sensitivity ana-
lysis (PSA) [20–25,27–31,33,35], 14 studies univariate sensi-
tivity analyses [20–25,28–35], and 1 study a deterministic
multivariate sensitivity analysis [31]. Descriptions on model
validation were found to be scarce. The majority of studies
performed cross-validation of the model outcomes to other
studies [21–26,28–35]. Other reported validation efforts
were double programming [33], face validity testing of the
input data [31], and testing of the fit of the dynamic model
to influenza incidence data [30,31]. In addition, Nagy et al.
[30] reported that the temporal patterns of influenza inci-
dence in Finland produced by the calibrated model were
validated against Finnish national surveillance reports. For
two studies, we did not find any model validation effort
reported [20,27].
3.3. Characteristics of the vaccination programs and
vaccines
Table 2 shows the characteristics of the vaccination programs/
vaccines, used as main inputs for the models. Most studies
focused on the whole population [20,22–24,27,29–33,35]. Two
studies focused on the vaccination of the elderly aged
≥65 years [21,34], while three studies included elderly aged
≥65 years and people < 65 years with clinical risk conditions
[25,26,28]. Vaccine coverage was predominantly based on
current national uptake rates of the influenza vaccination
program. Most studies focused on inactivated influenza vac-
cines only, while three studies also included a live-attenuated
vaccine (LAIV) for age-groups where this vaccine is licensed
[22,30,31].
All studies assumed equal vaccine efficacy of TIV and QIV
against influenza type A viruses, as both vaccines contain the
same influenza type A strains. Therefore, the vaccine efficacy
against influenza A is not explicitly taken into consideration in
this review. With regard to vaccine efficacy against influenza B,
most studies used data from published meta-analysis by Tricco
et al. [43] or DiazGranados et al. [44], while two studies [20,31]
adopted the vaccine efficacy reported for the US vaccination
program by Reed et al. [42]. Two studies did not differentiate
between vaccine efficacy against influenza A and influenza B
[24,29]. Almost all studies assumed that the vaccine efficacy of
TIV against influenza B is proportional to the relative match
with the circulating influenza B lineage in the last decade, with
the match failing in approximately half of the seasons. In case
of mismatched seasons, 11 studies assumed that TIV provides
cross-protection against the mismatched influenza B lineage
[20–24,26,28,31–34]. This level of cross-protection ranged
between 60% and 70% of the matched vaccine efficacy. For
QIV, studies predominantly applied the matched vaccine effi-
cacy of TIV against both B-lineages. Chit et al. [21] increased
the efficacy for 65+ year-olds from 49.0% for TIV to 50.7% for
QIV. Four dynamic modeling studies reported information
regarding the duration of the vaccine-induced protection
[23,24,30,31]. Two studies set the average duration of vaccine
protection at 1 year [23,31] and one study at 1.81 years [24]
(presented in [39]). The study of Nagy et al. [30] used a
probabilistic approach during the calibration process, sam-
pling durations from a range of 0.5–3 years using a uniform
distribution.
Figure 2 shows the incremental vaccine price of QIV over
TIV. Seven studies based the vaccine price of QIV on published
price lists [20,22–25,28,31], for instance, from the Centers of
Disease Control and Prevention vaccine price list. Other stu-
dies assumed a hypothetical vaccine price for QIV
[20,29,33,35], extrapolated the price increase from another
country [31], or explored a range of vaccine price differences
[27,34]. The incremental vaccine price varied considerably
across studies, ranging from US $1.25 for Canada [20] to US
$7.14 for the US [21]. Two studies assumed an equal vaccine
price (price parity) of QIV and TIV [26,30], while the study of
Uhart et al. [32] did not report vaccination costs, which, in
interpreting their results, also reflects price parity between QIV
and TIV. The three studies that included LAIV in their analysis


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































used the same price for trivalent LAIV and Q-LAIV [22,30,31].
Vaccine administration costs were excluded in this review, as
these costs are expected to be identical for TIV and QIV.
3.4. Influenza-related characteristics
Table 3 depicts an overview of the influenza-related input char-
acteristics. An important epidemiological parameter concerns
the probability to contract influenza among unvaccinated per-
sons (attack rate). Half of studies reported this parameter
[21,22,25–29,33]. In these studies, the probability of getting
infected was age-dependent, being higher for children than for
adults. Influenza cases were then split to subtype and lineage
using laboratory data on influenza-positive tests. No distinction
by age group was made in any study in the division of the
influenza cases over influenza A and influenza B. Dynamic mod-
els estimated influenza incidence by subtype and lineage inci-
dence by calibrating the model on time series of influenza-like
illness incidences combined with laboratory data on influenza-
positive tests [23,24,30,31]. Logically, studies with a dynamic
modeling approach rather reported a basic reproduction num-
ber (R0) than attack rates to demonstrate the spread of infection
within the population. Notably, the R0 reflects the average num-
ber of secondary infectious individuals produced by an average
primary infectious case in a totally susceptible population.
The number of influenza-related hospitalizations or deaths
was mostly calculated by multiplying the number of sympto-
matic influenza cases with the age-specific probabilities of
these events, while some studies applied event rates on the
study population directly. Other studies [34,35] used a top-
down approach similar to the model of Reed et al. [42],
estimating the number of influenza cases by dividing national
influenza-associated death rates with influenza case-fatality
ratios from the literature. Three studies used outcomes data
that were specific for influenza B [30,34,35]. Two studies from
Hong Kong used influenza B-specific hospitalization rates and/
or influenza B mortality rates [34,35], while Nagy et al. [30]
adapted subtype-specific outcomes estimated from the UK to
Finland. All other studies used the same outcome probabilities
across all influenza subtypes.
The QALY loss per influenza illness is calculated using two
main parameters, that is, the quality of life estimate of influ-
enza disease (utility) and the duration of the associated epi-
sode. Most studies split the duration and utility for influenza in
two different categories, that is, uncomplicated and compli-
cated influenza infections (including hospitalization) [21,23–
25,28,31,33–35], while three studies applied average estimates
of influenza-related QALY losses directly from the literature
[20,23,30]. One study ignored QALY losses due to influenza
illness assuming the disease to be transitory with negligible
impact on the overall quality of life, but included QALY losses
due to mortality [22]. We found that all studies based their
QALY estimates on published data from non-subtyped influ-
enza cases; that is, no studies used data specific for influenza
type B infection.
Influenza-related costs can be separated into health-care
and non-health-care costs. The health-care cost includes pre-
dominantly GP costs, hospitalization costs, and drug costs,
while non-health-care costs include costs for travelling and
productivity losses due to work loss. Overall, we found that
on average the studies for the US had higher health-care costs
than the studies from other countries. With regard to produc-
tivity losses of influenza-associated deaths, five studies
[24,27,28,30,35] used the human capital approach valuing
productivity losses until the age of retirement (Table 3).
Three studies [20,21,23] applied the friction cost methods,
assuming that an employee falling out of the production
process will be replaced by an unemployed person after a
friction period and that a certain elasticity of labor time and
production applies. Again, no studies used data on resource
use or absenteeism that was stratified by influenza subtype.
A final important parameter of interest concerns the dura-
tion of protection after natural infection. This parameter was

































Figure 2. The incremental vaccine price of quadrivalent influenza vaccine (QIV) as compared with trivalent influenza vaccine (TIV) used across included studies.
Prices are converted to 2015 US$. * These studies assumed price parity between QIV and TIV. † For these studies incremental vaccine prices of inactivated vaccines
were shown only. For live-attenuated influenza vaccines (LAIV), price parity was assumed between LAIV and quadrivalent LAIV. ‡ The study of Uhart et al. [32] did
not include vaccination costs, which reflects price parity.
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































All these studies assumed that the duration of naturally
acquired immunity was longer than vaccination-acquired
immunity. Two studies used an average duration of naturally
acquired immunity for influenza B of 12 years [23,31], while
one study used a duration of 7 years [24] (as presented in
[39]). The study of Nagy et al. [30] used a probabilistic
approach for this parameters during their calibration process,
sampling input values between 0.5 and 75 years using a uni-
form distribution.
3.5. Study outcomes
The effectiveness and cost-effectiveness results of QIV versus
TIV are summarized in Table 4. We found that the impact of
QIV on influenza-related morbidity and mortality varied con-
siderably across studies. Overall, dynamic models reported
higher reductions of influenza-related morbidity as compared
with static models. The impact of QIV on the total number of
influenza cases (type A and B) as compared with TIV ranged
from a reduction of 0.15% in the US using a static model [22]
to 6.47% in the US using a dynamic model [29]. Studies pre-
senting results for influenza B only found reductions of 29.2%
for the US using a dynamic model [23] and 14.7% for Hong
Kong using a static model [35]. One study focusing on elderly
in Hong Kong presented incidence rates of averted influenza B
cases, finding a total reduction of 118–508 per 100,000 person
years [34]. Impact on influenza-related mortality was generally
estimated somewhat higher than influenza morbidity
(Table 4).
Figure 3 shows the cost-effectiveness results of QIV versus
TIV, expressed as incremental cost-effectiveness ratios (ICERs).
From a payer’s perspective, a cost-effectiveness study for
Finland [30] and cost-comparisons for Australia and the
European Union [26,32] found that QIV would result in cost-
savings (Figure 3A). However, these studies assumed price
parity between QIV and TIV [26,30] or excluded vaccination
costs in their analysis [32]. The highest ICER was found by Chit
et al. [21] for the US, estimating an ICER of US $145,705/QALY
using a static model. From a societal perspective, cost-savings
were reported by one static cost-comparison model in the US
[27] and two dynamic models in the US and Germany [24,29]
(Figure 3B). The highest ICER was in a scenario found by You
et al. [34] for Hong Kong, estimating that in a season with a
good match and an incremental vaccine price of US $10, the
ICER could increase to US $254,245 per QALY gained [34] from
the societal perspective.
Most studies drew a conclusion on whether implement-
ing QIV could be regarded as a cost-effective intervention.
However, most countries do not have an official willingness-
to-pay (WTP) threshold, whereas the National Institute for
Health and Clinical Excellence (NICE) in the UK considers a
WTP threshold of US$29,070–43,600 (£20,000–30,000) per
QALY for vaccines [45]. When no official thresholds were
available, studies often referred to WTP thresholds used in
earlier published cost-effectiveness studies or to recommen-
dations of the World Health Organization (WHO), suggesting
that an intervention is cost-effective if the ICER is below
three times the gross domestic product per capita of a






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































US would result in a WTP threshold of US $150,000 per
QALY gained. All cost-utility studies concluded that vaccina-
tion with QIV would be at least cost-effective as compared
with TIV, when official or hypothetic thresholds were con-
sidered [20–25,28–31,33–35].
3.6. Key drivers of cost-effectiveness results
Parameters that were found to be of highest impact on cost-
effectiveness outcomes are shown in Table 4. The four most
reported key parameters were vaccine price of QIV, the level of
cross-protection of TIV against the mismatched B virus strain,
the distribution of influenza incidence between influenza A
and influenza B, and the level of vaccine match of TIV with the
circulating B lineages (Table 4). Obviously, higher vaccine price
differences between QIV and TIV resulted in less beneficial
cost-effectiveness outcomes. For instance, Nagy et al. [30]
found that when an incremental vaccine price of US $3.96
for QIV over TIV would be assumed instead of price parity,
the estimated amount of cost saving would be reduced by
30%. Also, the high ICER of US $139,027 per QALY gained for
the US elderly by Chit et al. [21] could be explained by a
relatively high vaccine price of QIV.
The impact of cross-protection of TIV to the opposite B
virus strain on the cost-effectiveness was explicitly illustrated
by the study of de Boer et al. [23], showing that decreasing the
level of cross-protection from 70% to 50% in the US turned
the ICER from US $27,891 per QALY gained into cost-saving/
dominant. Furthermore, the circulation and distribution of,
respectively, influenza A and influenza B and related vaccine
matching/efficacy had also a strong effect on the ICER. For
example, van Bellinghen et al. [33] noted that, in a scenario of
0.4% circulation of influenza B, the ICER would increase to US
$587,000 per QALY gained and, in a scenario of 30% circula-
tion of influenza B, the ICER would decrease to US $2,200 per
QALY gained, both as compared to a base case of US $8,611
per QALY at 24.8% circulation. Additionally, in a scenario of
99.0% matching of TIV with the circulating influenza B virus












































Figure 3. Incremental cost-effectiveness ratios (ICER) in US$/quality-adjusted life year (QALY) gained of quadrivalent influenza vaccine as compared with trivalent
influenza vaccine. ICERs are converted to 2015 US$. Static models are presented in black and dynamic models in grey. Results are presented from a payer’s
perspective (Figure 3A) and the societal perspective (Figure 3B). CS: Cost-saving. *:The ICERs of Chit et al [20] . and You et al. [34] (highest) are not presented due to
graphical issues. Chit et al. [20] found an ICER of US $145,700 per QALY from the healthcare payer’s perspective and US $139,200/QALY from the societal perspective.
You et al. [34] (highest) found an ICER of US $254,200/QALY from the societal perspective. †UK1: Vaccine uptake rate of 52.5% in children aged 2-17 years. UK2:
Vaccine uptake rate of 70% in children aged 2-17 years.





























This is the first systematic review concerning the health-eco-
nomic value of QIV so far. According to the current literature,
QIV appears to be a cost-effective intervention as compared
with TIV. All studies found that QIV resulted in valuable health
benefits as compared with TIV by reducing influenza related
morbidity and mortality within a range of 0.15–6.5%.
Additionally, QIV was estimated to save costs to the healthcare
system and to society, partially or even fully compensating for
the higher vaccine price of QIV compared to that of TIV.
Although conclusions on cost-effectiveness were generally
similar, we found substantial heterogeneity across cost-effec-
tiveness results. ICERs varied from cost-saving to $146,000
from a health-care payer’s perspective and cost-saving to
$140,000 from a societal perspective. Identified key para-
meters to cost-effectiveness outcomes included vaccine
price, circulation of the B-virus not included in TIV and cross-
protection of TIV against the opposite B-virus.
Modeling approach was found to be important with regard
to cost-effectiveness results. Despite the recommendations of
Quinn et al. [13] and working groups on cost-effectiveness
analyses of vaccines [40,47], only five studies used a dynamic
transmission model. We found that dynamic models predicted
a higher impact of QIV on influenza morbidity than static
models, resulting in better cost-effectiveness outcomes.
Vaccination reduces the overall influenza transmission within
a population. As static models use a constant force of infec-
tion, they do not quantify the indirect impact of vaccination.
Therefore, we recommend that, although static models can be
informative for an initial preliminary analysis, dynamic models
are required to study the full impact of QIV on health-eco-
nomic outcomes. Obviously, the downside of this recommen-
dation is that dynamic models demand more (fine-grained)
input data than static models [41].
Notably, the impact of modeling approaches depends on
the current vaccination policy of the studied country.
Countries with universal influenza vaccination recommenda-
tions, such as the US, have relatively high vaccination cover-
age among children. As children seem to represent an
important group in influenza transmission [48,49], the addi-
tional impact of dynamic models over static models will be
higher in countries with universal vaccination as compared
with countries restricting influenza vaccination to elderly and
specific high-risk groups. Additionally, when – from a societal
perspective – cost savings due to (parental) work loss are
taken into account, potentially better cost-effectiveness out-
comes may ensue. On the other hand, complication rates are
highest among the elderly. Therefore, we would emphasize
that cost-effectiveness outcomes might be highly influenced
by the target group of the vaccination program.
An important key aspect to cost-effectiveness outcomes is
whether cross-protection of TIV against the mismatched B
virus is taken into account. As mentioned by Quinn et al.
[13], recent evidence suggests that cross-protection of TIV to
the opposite influenza B virus exists, potentially diminishing
the impact of QIV significantly [43,44]. Our review shows that
the majority of studies included cross-protection in their ana-
lyses. Most studies referred to systematic reviews by Tricco
et al. [43] and DiazGranados et al. [44], estimating that the
vaccine efficacy of TIV against the non-included B virus strain
is 65–70% of the matched efficacy. Studies on single influenza
seasons confirmed the finding of cross-protection during the
2012–2013 season in the US and Canada [50,51], but not
during the 2011–2012 season in Canada [50]. Additionally, a
recently published serological study demonstrated that anti-
bodies elicited with inactivated TIV containing a Victoria-line-
age strain were highly cross-reactive to a Yamagata-lineage
strain [52]. As current evidence supports the existence of
cross-protection, we endorse the inclusion of this aspect in
cost-effectiveness models. However, as bias cannot be ruled
out due to pre-existing immunity as a result of prior vaccina-
tion or natural infection, the exact estimate is unclear.
Therefore, we highly recommend to perform sensitivity ana-
lyses on this parameter.
Another key parameter influencing cost-effectiveness out-
comes is the vaccine price. Many studies had to make assump-
tions on the price premium of QIV as compared with TIV, since
no official vaccine price was available at the moment of ana-
lysis. Therefore, the vaccine price should be taken into account
when interpreting results, as for instance cost-effectiveness
studies assuming a price parity between QIV and TIV will
almost automatically result in cost-saving outcomes. On the
other hand, assuming price parity in the absence of an official
QIV price and just showing the expected net health benefit of
QIV over TIV avoids drawing the wrong conclusion. Cost-effec-
tiveness results could then be easily updated when a vaccine
price becomes available. Currently, price lists of the US CDC
show that the vaccine manufacturers increased the price of
inactivated QIVs significantly, at around 50% higher than inac-
tivated TIVs, although there was no price increase shown for
Q-LAIV as compared with trivalent LAIV [53]. However, in
large-scale public health programs, such as influenza vaccina-
tion, vaccines might be procured at relatively lower prices
than indicated by the list prices.
Cost-effectiveness results also tend to be highly sensitive to
the level of circulation of the influenza B virus. In seasons with a
proper vaccine match and no co-circulation of both B lineages,
the effect of QIV over TIV is likely to be negligible. This was
highlighted in some studies that analyzed the impact of QIV
retrospectively over the period 2001–2010, demonstrating a
wide variation in cost-effectiveness results between different
seasons [27,33,34]. As any influenza virus, influenza B incidence
varies across countries and regions [4,5]. For instance, three
studies estimated the proportion of mismatched influenza B
infections at 50% of the total influenza B infections in the US
between 1999 and 2009, in line with 52.6% in Australia
between 2002 and 2012, and 52.4%, in the UK between 2000
and 2010 [22,26,33]. However, the study by Heikkinen et al. [54]
found that this proportion was only 41.7% in Finland in the
period 1999–2012. Therefore, studies analyzing the retrospec-
tive impact of QIV should aim to use country-specific data.
We noticed that most studies used equal estimates of
resource use and costs across all influenza subtypes. As sug-
gested by Quinn et al. [13], influenza B might be associated
with higher morbidity in children as compared with the
elderly. In the elderly, highest hospitalization and mortality




























rates were found for the influenza A/H3N2 subtype, followed
by influenza B virus and the A/H1N1 subtype. Usage of out-
come estimates that are not specified by seasonal influenza
subtype might therefore be considered nonoptimal. However,
a study of Mosnier et al. [55] showed that despite differences
in age-distribution between influenza A and influenza B, no
differences on clinical severity were found between influenza
virus types and subtypes among GP visiting influenza cases.
Notably, when influenza B causes less severe disease in adults
and the elderly as compared with influenza A, patients with
influenza B will be underrepresented at medical facilities to
undergo laboratory testing for subtype. This may complicate
the split of influenza cases by subtype as performed in static
models. A further complication might be that available data
on laboratory tests were often subtyped between A and B, but
not between B/Vic and B/Yam [56]. Regarding influenza-
related mortality, the impact of QIV might be overestimated
when A/H3N2 is indeed related to higher mortality in elderly
than influenza B. As data on influenza B incidence and its
resource use are still not widely available, more evidence on
incidence and resource use by subtype would be desirable to
improve the validity of cost-effectiveness results.
Next to nonlinear influenza epidemiology by age and sub-
type, pre-existing immunity due to prior natural influenza
infection or vaccination history might induce inaccuracy.
Duration of naturally acquired immunity is expected to be
influenced by the natural waning of immunity within the
individual as well as the drift of influenza viruses over time
[57]. However, evidence on this aspect is, to the best of our
knowledge, still scarce. Dynamic modeling studies included in
this review, predominantly derived inputs for this parameter
from a study of Vynnycky et al. [58]. This study calibrated a
dynamic model on influenza incidence patterns of the UK,
with optimal fit occurring when durations of naturally
acquired immunity were set at 6 years for influenza A and
12 years for influenza B. Also a study by Eichner et al. [39],
describing the influenza dynamics for Germany, assumed a
longer naturally acquired immunity for influenza B as com-
pared with influenza A/H3N2 (3.5 years versus 7 years). The
study of Nagy et al. [30] found eligible simulations during their
calibration process for durations of naturally acquired immu-
nity against influenza B ranging between 0.5 and 75 years. A
recent dynamic modeling study from Japan [59], however,
estimated much shorter durations of natural immunity against
influenza B than the above mentioned studies, estimating
1.15 years for B/Vic and only 0.08 years for B/Yam, although
this does not align well with current knowledge on the rela-
tively conserved antigenic nature of influenza B [60]. For the
duration of vaccine-induced protection, a recent study by
Kissling et al. [57] suggested that protection against influenza
B was longer than that against influenza A/H3N2, possibly due
to a more rapid antigenic drift of A/H3N2 [61]. Related to this
aspect, Höpping et al. [62] recently presented an approach to
optimize the effectiveness of TIV by choosing the included
influenza B strain on the basis of the population’s pre-existing
immunity instead of taking the virus strain that circulated in
the prior season. They argued that by taking into account the
time since vaccination, antigenic drift, and serological para-
meters of each B virus strain, the level of residual protection
against B/Yam and B/Vic could be estimated. By selecting the
influenza B virus strain with the lowest residual protection,
high protection levels against both influenza B viruses would
be present after vaccination, potentially giving a better pro-
tection in case of a vaccine mismatch. Although this strategy is
expected to be still inferior to QIV, Höpping et al. [62] sug-
gested that it might at least partially capture the benefit of
QIV, without any additional vaccine costs. So far, no study has
ever compared the cost-effectiveness of QIV versus TIV using
this ‘Höpping’ approach, which, however, might be of interest
and complement existing studies.
With regard to the quality of reporting according to the
CHEERS criteria [15], we found that adherence to this checklist
was acceptable. However, we noticed that only a few studies
provided arguments whether the chosen time horizon was
appropriate to capture all the various effects and conse-
quences of the intervention. Indeed, influenza is often consid-
ered a seasonal issue, with each year different types and/or
subtypes of influenza predominantly circulating, varying in
disease severity. Yet, considering the fact that influenza is an
annual recurrent disease with potential crossover effects from
season to season, a time horizon of more than one year is
needed to capture all the various effects and consequences of
vaccination policies. Hence, models should transparently
argue whether their chosen time horizon is long enough to
include relevant subsequent effects.
A second concern that emerged from the analysis using the
CHEERS checklist relates to the exact descriptions of the popu-
lation and instruments used to estimate the impact of influ-
enza on quality-of-life. We noticed that many of the included
studies used utilities from outdated studies (mostly other
models) that were based on small sample sizes. Updating a
systematic review on studies measuring the impact of quality-
of-life estimated of influenza morbidity by Van Hoek et al. [63],
we found that the evidence on this aspect is still limited [64].
Although two studies were published that used EQ-5D to
measure quality-of-life of influenza morbidity based on larger
sample sizes [63,65], generalizability might be limited as these
analyses were conducted among patients infected with the
pandemic H1N1 influenza strain. As pandemic H1N1 was gen-
erally seen as a milder variant of disease than A/H3N2 in
adults, these values might not be truly representative for
seasonal influenza in general [66]. Therefore, we recommend
precise studies on estimating the quality-of-life in laboratory-
confirmed seasonal influenza patients with standardized
instruments.
The reporting regarding performed validation processes
was found to be limited. A proper validation process of the
model and its transparent reporting will improve the credibil-
ity of the model outcomes. Although most studies performed
cross-validation of model outcomes to similar studies, these
comparisons are mostly hampered by differences between
model types and/or model inputs. Notably, as the inclusion
of parameters such as waning of immunity or antigenic drift of
viruses strongly enhance the complexity of (dynamic) models,
validation techniques on the computerized model and its out-
comes will become increasingly important. Obviously, the
transparency of a model increases considerably by making
the model publicly available, which – to the best of our




























knowledge – was only done for the model used in the
Canadian study by Chit et al. [20]. In addition, we would
advocate the use of structured model validation checklists,
as researchers tend to do more validation efforts than they
report in their manuscripts [67].
Finally, we found that the majority of the studies were
funded by pharmaceutical companies. We feel that, in addi-
tion to these sponsored studies, also publicly funded eco-
nomic evaluations of QIV are needed to validate the findings
from industry-funded studies. Furthermore, there were no
studies performed in low- and middle-income countries
(LMICs), where it would also be valuable to know if more
restricted budgets could be better spent on QIVs or TIVs.
Indeed, due to differences in demographics, comorbidities,
and healthcare facilities, results from industrialized countries
are not directly transferable to LMICs. For instance, as influ-
enza B rather tends to infect adolescents and young adults
than elderly, the impact might be higher in LMICs which
generally have younger populations. An individual-based
modeling exercise found that QIV would reduce influenza-
related hospitalizations and deaths by 18% as compared
with TIV in a community in South Africa between 2003 and
2013, while this was only 2% in Australia in the same per-
iod [68].
The main limitation of our study is that our search was
restricted to the English language. A major strength of our
study is that we systematically searched for economic evalua-
tions of QIV using multiple databases. We converted study
results to the same price year and corrected for differences in
purchasing power to enhance comparability. Another strength
is that we checked whether the key challenges mentioned by
Quinn et al. [13] were addressed properly. We also included
studies in which the primary goal was not to evaluate the cost-
effectiveness of QIV as compared with regular TIV, but for
instance with high-dose TIV or adjuvant TIV [21,29], with cost-
effectiveness of QIV emerging as an additional result. Chit et al.
[21] estimated that a high-dose TIV, containing four times
higher viral-loads as compared with regular TIV, would be
more effective in preventing influenza disease in US elderly as
compared with QIV. From the societal perspective, the authors
estimated that high-dose TIV would be cost-saving as com-
pared with QIV or US $5,157 per QALY gained as compared
with regular TIV. Mullikin et al. [29] found from a societal
perspective that TIV adjuvanted with the squalene-containing
oil-in-water emulsion MF59 would be cost-saving in US elderly
as compared with regular TIV and QIV.
In conclusion, published evidence of the economic conse-
quences found that quadrivalent influenza vaccination is
expected to be a cost-effective intervention as compared
with TIV. However, the cost-effectiveness potential is strongly
related to the price difference between QIV and TIV, and the
level of cross-protection that TIV provides against the B virus
strain that is not included in the vaccine. In other words, the
benefits of QIV will vary strongly by season according to the
match of TIV with the circulating B virus strain. It is therefore
recommended to assess the impact of QIV versus TIV using
data from multiple influenza seasons, which on average will
give a better reflection of influenza B virus strain circulation
from one year to another. As previously discussed by Quinn
et al. [13], we support the inclusion of cross-protection of TIV
against the mismatched B virus, the use of influenza B-specific
data to estimate the disease burden, and the use of dynamic
models. As we noticed that influenza B-specific data on dis-
ease burden and costs remains scarce, we recommend more
research into these topics.
5. Five-year view
With regard to the future, we endorse studies aiming to
unravel the immunogenicity of natural influenza infection
and vaccination. Uncertainty around potential influential
aspects like cross-protection, duration of vaccine-induced
and natural immunity is large. Further insight into these
aspects will improve the understanding and modeling of
influenza transmission dynamics. However, as modeling of
the relationship between (drifting) influenza viruses and
immunity in the human population will increase the complex-
ity of dynamic modeling, we would also advocate proper and
transparent model validation processes in order to guarantee
continued adequate evidence-based immunization decision-
making.
Although newly developed influenza vaccines, like high-
dose vaccines and adjuvanted vaccines, have been shown to
have improved immunogenicity and may, potentially,
induce better cross-protection as compared with standard
vaccines [69,70], their efficacy toward unmatched viruses
remain to be analyzed. To definitively overcome this issue,
the development of broad-spectrum influenza vaccines is
currently widely explored [71]. These so-called ‘universal’
vaccines aim to induce a humoral response against viral
antigens or antigenic epitopes which are not affected by
antigenic drift or they may activate a different immune
pathway like the cellular immune response [60]. Universal
vaccines may thus provide protection against not only many
different viral strains and drift variants, but also against
antigenically shifted viruses with pandemic potential. A
recent modeling exercise demonstrated that such broad-
spectrum vaccines have the potential to interrupt influenza
transmission even at moderate uptake levels [72]. Although
some promising broad-spectrum vaccines have entered
already the phase of testing in clinical trials [60], it remains
uncertain whether and when such vaccines will become
publicly available. Certainly, duration of vaccine-induced
protection will become a very important aspect with regard
to the public-health impact and cost-effectiveness of these
vaccines.
Key issues
● Quadrivalent influenza vaccines (QIVs) contain one addi-
tional influenza B strain as compared with trivalent influ-
enza vaccines (TIVs).
● Quadrivalent influenza vaccination is supposed to provide
better protection in seasons with a mismatch between TIV
and the circulating B virus lineage or in seasons with co-
circulation of both influenza B lineage.




























● In this review, we identified 13 cost-effectiveness studies
and three cost-comparisons of QIV versus TIV.
● Studies predominantly estimated QIV to be a cost-effective
or even cost-saving intervention from payer’s and societal
perspectives.
● Levels of mismatched influenza B circulation, cross-protec-
tion of TIV to the mismatched B virus and the QIV price
premium were identified as key factors influencing health-
economic outcomes.
● Enhanced use of dynamic transmission models is recom-
mended as these models account for indirect effects of
vaccination on unvaccinated individuals.
● As disease burden might differ by influenza subtype, cost-
effectiveness studies should be improved with subtype-
specific data and increased evidence on this aspect should
be made available.
● Better understanding of influenza immunogenicity by nat-
ural infection and vaccination is needed to improve simula-
tion of influenza dynamics.
● Given the increasing complexity of (dynamic) influenza
models, systematic validation of the model and its out-
comes is strongly recommended.
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